QuidelOrtho Corporation (NASDAQ:QDEL) (“QuidelOrtho”), a global provider of innovative in vitro diagnostics technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today that its board of directors has authorized the repurchase of up to $300 million of shares of QuidelOrtho’s common stock over the next two years.
Baird Maintains Neutral on Under Armour, Raises Price Target to $10
Baird analyst Jonathan Komp maintains Under Armour (NYSE:UAA) with a Neutral and raises the price target from $9 to $10.
